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Abstract
Background
Ablative fractional photothermolysis (aFP) using a CO2 laser generates multiple small diam-
eter tissue lesions within the irradiation field. aFP is commonly used for a wide variety of der-
matological indications, including treatment of photodamaged skin and dyschromia, drug
delivery and modification of scars due to acne, surgical procedures and burns. In this study
we explore the utility of aFP for treating oncological indications, including induction of local
tumor regression and inducing anti-tumor immunity, which is in marked contrast to current
indications of aFP.
Methodology/Principal findings
We used a fractional CO2 laser to treat a tumor established by BALB/c colon carcinoma cell
line (CT26.CL25), which expressed a tumor antigen, beta-galactosidase (beta-gal). aFP
treated tumors grew significantly slower as compared to untreated controls. Complete
remission after a single aFP treatment was observed in 47% of the mice. All survival mice
from the tumor inoculation rejected re-inoculation of the CT26.CL25 colon carcinoma cells
and moreover 80% of the survival mice rejected CT26 wild type colon carcinoma cells,
which are parental cells of CT26.CL25 cells. Histologic section of the FP-treated tumors
showed infiltrating neutrophil in the tumor early after aFP treatment. Flow cytometric analy-
sis of tumor-infiltrating lymphocytes showed aFP treatment abrogated the increase in
regulatory T lymphocyte (Treg), which suppresses anti-tumor immunity and elicited the
expansion of epitope-specific CD8+ T lymphocytes, which were required to mediate the
tumor-suppressing effect of aFP.
Conclusion
We have demonstrated that aFP is able to induce a systemic anti-tumor adaptive immunity
preventing tumor recurrence in a murine colon carcinoma in a mouse model. This study
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demonstrates a potential role of aFP treatments in oncology and further studies should be
performed.
Introduction
Fractional Photothermolysis (FP) is a laser-assisted treatment producing a pattern of micro-
scopic treatment zones (MTZs) in biological tissue [1]. Ablative FP (aFP) generates MTZs
which are characterized by a central “hole” of physically-removed (ablated) tissue, typically
surrounded by a small cuff of thermally damaged tissue, while non-ablative FP (nFP) generates
MTZs by small zones of thermally damaged tissue in the absence of any centrally ablated
(removed) tissue. [2, 3]. The diameter of the MTZs is typically less than approximately 0.5
mm. FP techniques are characterized by direct exposure of only a small fraction of the tissue to
the laser radiation (typically only 5–27% of the treatment area), with most of the tissue being
spared or unexposed [4]. FP is currently used for a wide spectrum of dermatological indica-
tions including, but not limited to, treatment of photodamaged skin, dyschromia, rhytides,
and various kind of scars including acne, surgical and burn scars [1, 5–8]. Ablative FP has
been used in combination with photodynamic therapy (PDT) to treat skin cancer; however, in
conjunction with this indication, aFP is mainly used to provide enhanced topical delivery of
the photosensitizing drug by increasing permeability of the skin [9, 10]. Non-ablative FP has
been used to treat precancerous skin lesions (actinic keratoses). However such treatments have
been limited to direct irradiation of local skin regions, and no studies to date have investigated
production of systemic effects using FP methods [11]. Also FP is typically not used to treat
tumors as the current paradigm of tumor treatment is to destroy the entire tumor volume
rather than inducing damage only to a small portion of the tumor.
Photodynamic therapy (PDT) has been used successfully for local cancer therapy. Various
types of cancer have been treated with PDT including, but not limited to, skin cancer [10]],
lung cancer [12, 13], bile duct cancer [14, 15], and pancreatic cancer [16]. The response to
PDT treatment is dependent on the cancer type and cell lines present. Mroz et al. [17] reported
in a murine cancer model that PDT of an intradermally inoculated CT26.CL25 tumor induced
local remission as well as a systemic tumor-specific immune response, resulting in regression
of a remote, untreated tumor (abscopal effect). It has thus been observed that PDT is able to
induce a systemic, tumor specific anti-tumor immunity. However, PDT has some shortcom-
ings because it is a drug-device combination treatment that requires the administration of the
photosensitizing drug in a dose dependent and time-sensitive manner. The PDT effect also
depends on the bioavailability of the photosensitizer and requires an oxygen rich environment
[18–20]. Both requirements can be a challenge within tumors, which are often characterized
by blood vessel compression and hypoxemia due to the tumor growth [21, 22]. As most non-
dermatological tumors require systemic application of the photosensitizer, the resulting
requirement for prolonged light avoidance of patients is another downside of systemically
delivered PDT.
In contrast, FP is a laser-only treatment and does not require bioavailability of a drug within
the tumor tissue. FP of skin is a simple and quickly performed procedure, which is routinely
performed for the above-mentioned dermatological, non-cancerous indications. FP of non-
dermatological tissues could also be performed easily, although anatomical site-specific laser
delivery applicators might be required for non-dermal tissue irradiation. Motivated by these
potential advantages as compared to PDT treatments, we have investigated effects of aFP itself
in the absence of any photosensitizer on systemic tumor-specific immune responses. Our
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objective was to investigate if aFP is has some promise to induce any anti tumor effects at all
which is in marked contrast to the current applications of FP.
Results
Fractional laser beam penetrates the skin and the tumor
Fig 1A shows the appearance of the skin surface immediately after ablative fractional laser exposure.
The fairly regular alignments of the ablated holes can be seen. There is absence of graying or blister-
ing of the skin immediately after laser exposure, which suggests an absence of thermal bulk injury.
The CO2 laser-induced ablative MTZs reached well into the tumor tissue. We have analyzed multi-
ple samples and found reproducible an average lesion depth of approximately 3.1 mm from the sur-
face of the skin using a laser energy of 100 mJ (Fig 1B). The ablated holes, which are characteristic of
aFP procedures, could be seen. However, these ablated holes appeared to be collapsed and distorted
within the tumor tissue. Representative horizontal sections of the aFP-treated tissue were consistent
with the morphology seen in the vertical sections (Fig 1C). The horizontal sections exhibited a regu-
lar pattern consistent with the scanning pattern of the laser exposures. The thermal injury zone, as
marked by loss of blue NBTC stain, exhibited a thickness of less than 40 μm surrounding the laser
induced holes in the tissue. Diameter of the MTZ (The thermal injury zone + laser-ablated holes)
was approximately 250 μm. Assuming a cylinder geometry (volume = height x diameter2 x π/ 4) the
total volume of single MTZ in the tumor was 0.15 mm3. This is an estimate as it is difficult to calcu-
late the exact volume because the channels were partially collapsed (decreased diameter) but also
exhibited some irregular lateral protrusions of the channels (increased thermally affected volume).
Fig 1. Ablative fractional photothermolysis. (A) photo of skin surface appearance immediately after ablative
fractional photothermolysis (100 mJ pulse energy). Black arrow indicates one of the laser-generated holes
formed by tissue vaporization/ablation. There is an absence of graying or blistering immediately after laser
exposure, which also suggests an absence of major thermal injury. (B) H&E-stained CT26.CL25 tumor
immediately after the ablative fractional photothermolysis (aFP) laser treatment with a pulse energy of 100mJ.
White arrows indicate an ablated hole which is characteristic of aFP procedures. The ablated hole appeared to
be collapsed and distorted within the tumor tissue. (C) CT26.CL25 tumor immediately after aFP, stained by
NBTC staining that shows vital cells as a blue color. White arrows indicate dead cells caused by physical effects
of the laser treatment. Most of the tissue within the aFP volumes exhibited a blue staining, indicating an absence
of widespread thermal injury or tissue bulk heating.
https://doi.org/10.1371/journal.pone.0184852.g001
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The projected MTZ / tumor surface ratio was approximately 8%. However MTZs did not
reach to approximately more than 2/3 of the tumor depth. Therefore the total MTZ / tumor vol-
ume ratio was approximately 5%. It was notable that the lumen of the laser-ablated holes were
irregular and exhibited some irregular lateral protrusions of damaged tissue that extended into
some of the spaces between the irradiation locations of the scanning pattern. Such protrusions
would be consistent with hot steam jets originating from the individual laser-irradiated sites
due to the explosive nature of the laser-assisted ablation process. Most of the tissue within the
aFP treatment volumes exhibited a dark blue NBTC staining, indicating an absence of wide-
spread thermal injury or tissue bulk heating.
aFP is significantly effective against local primary tumors
aFP laser irradiation was performed 8 days after tumor inoculation. The aFP significantly led
to a reduction in tumor volume and growth rate of beta-gal antigen positive CT26.CL25
tumors after the treatment (P< 0.005: Fig 2A). Significant tumor reduction was observed even
in non-cured CT26.CL25 tumor-bearing mice (P< 0.005: Fig 2B). 7 of 13 mice (53%) with
CT26.CL25 tumor treated with aFP were euthanized between days 24 and 42 due to local
tumor recurrence and regrowth (Fig 2C). Tumors shrank in 6 mice of the aFP group, but such
shrinkage occurred in only 1 mouse from the control group (Fig 2C). The significance value
for the difference between the survival curves is: control vs. aFP (p<0.05).
Repeated experiments are shown in S2 Fig.
Fig 2. Tumor volume and survival curves after aFP treatment. (A) tumor volume curves of mice in the control group
and aFP group after tumor inoculation. ***P < 0.0001. The bars represent SD. (B) tumor volume curve of mice in the
control group, and tumor volume curves of cured mice and non-cured mice which are split from original curve in aFP group.
* P < 0.01, ** P < 0.005 comparing control to aFP-non cured group. The bars represent SD. (C) Kaplan-Meier survival
curves of mice receiving tumor inoculation. The significance values for the difference between the survival curves are:
control vs. FP (p < 0.05).
https://doi.org/10.1371/journal.pone.0184852.g002
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aFP induces development of long term anti-tumor immunity
To assess the presence of any induced systemic immunity, we performed a rechallenge
experiment following the aFP laser treatment. Six mice in the aFP group which survived for
more than 90 days after the aFP, were subsequently inoculated intradermally with CT26.
CL25 in the contralateral (right) thigh. Six age-matched naive mice were inoculated with
the same number of CT26.CL25 cells, respectively, in the right thigh as a control. The tumor
on the naive mice in the control groups progressed over time (Fig 3A). Tumors on the sur-
vival mice in the aFP-treated group did not appear to progress (Fig 3A). They remained
tumor–free for at least another 60 days following the inoculation (Fig 3B). The significance
values for the differences between the survival curves are: control mice vs. survival mice
(p<0.005).
To investigate the role of artificial tumor antigen (beta-gal) in developing anti tumor immu-
nity, we performed a rechallenge experiment using CT26 wild type (CT26WT) colon carcinoma
cells, which are beta-gal negative parental carcinoma of CT26.CL25 cells. Mice cured from
CT26.CL25 tumor and survived tumor free for 90 days after aFP treatment were inoculated
with CT26WT cells. Interestingly 4 of 5 survival mice rejected CT26WT tumor and remained
tumor–free for another 60 days following the inoculation (Fig 3C).
Repeated experiments are shown in S3 Fig.
Fig 3. Tumor volume and survival curves after rechallenge test. (A) mean tumor volume curves of the mice in
the control group and survival mice after the rechallenge test. These mice were each inoculated with 3.5 x 10^5
CT26.CL25 cells intradermally in the contralateral (right) thigh against previous inoculation. Tumors on the survival
mice in the aFP group did not appear to progress. (B) Kaplan-Meier survival curves of mice receiving the rechallenge
test with CT26.CL25 cells. The significance values for the difference between the survival curves are: control mice
vs. survival mice (p<0.005). (C) Kaplan-Meier survival curves of mice receiving the rechallenge test with CT26
wildtype cells which is parental tumor of CT26.CL25 cells. The significance values for the difference between the
survival curves are: control mice vs. survival mice (p<0.005).
https://doi.org/10.1371/journal.pone.0184852.g003
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aFP induce accumulation of the N1 neutrophils
To investigate whether innate immunity was induced after the fractional laser treatment, flow
cytometry and immunohistochemistry for neutrophil was performed. Flow cytometric analysis
showed aFP led to a significant increase in neutrophil on day 1 after aFP, proportions of neu-
trophil compared with CD45+ CD3- leukocytes were significantly higher in the aFP group
than in control (p< 0.01: Fig 4A). Fig 4B and 4C are representative images of flow cytometry
on day 1 after aFP in the control group and aFP group respectively. The number in the figures
represents proportion of neutrophils compared with CD45+ CD3- leukocytes. Although tumor
volume in the aFP group were smaller than in control group, more neutrophils could be
counted (Fig 4B and 4C). We also detected NK cells, B lymphocytes and macrophage using
flow cytometry however there were no significant differences between both groups (S1A Fig).
Immunohistochemical staining also showed that the neutrophils apparently accumulated in
the tumors in the aFP group more than in the control group on day 1 after aFP (Fig 4D–4F).
Tumor-infiltrating neutrophils in control group showed CD206 expression, which indicates
N2 protumorigenic neutrophil [23] (Fig 4G). However the neutrophil in aFP group did not
Fig 4. Immunochemical staining and flow cytometric analysis for tumor infiltrating neutrophils. (A)
proportion of neutrophil compared with CD45+CD3- leukocytes in the tumor of flow cytometric analysis. (B and
C) representative images of flow cytometry for neutrophil on day 1 after aFP in the control group and aFP
group respectively. The number in the figures represents proportion of neutrophil compared with CD45+CD3-
leukocytes. (D and E) immunohistochemical staining for neutrophil in the tumor 1 days after aFP in the control
group and aFP group respectively. Cells stained as red color are neutrophils. Inset shows multi nucleated
neutrophils as the dominant immune infiltrate seen in H&E-stained aFP-treated tumor. (F) magnified image of
neutrophil in figure (4D, G and H) immunohistochemical staining for CD206-expressing neutrophil in the tumor
1 days after aFP in the control group and aFP group respectively. Cells stained as yellow color are neutrophils
expressing CD206.
https://doi.org/10.1371/journal.pone.0184852.g004
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show CD206 expression, which indicates N1 antitumorigenic neutrophil [23] (Fig 4H). These
results imply aFP induces infiltration of antitumorigenic neutrophil into the tumor. Addition-
ally, we found there were apoptotic tumor cells around the site of N1 neutrophils accumulation
within the tumor in the aFP group (Fig 5A and 5B).
Repeated experiments are shown in S4–S6 Figs.
aFP abrogates the increase in regulatory T lymphocyte (Treg) and
develop epitope specific CD8+ T lymphocytes
To investigate if the adaptive immune system was affected by aFP, we measured the ratio of
Treg and CD8+ T lymphocytes in tumor infiltrating lymphocytes (TILs) using flow cytometry.
Each time point included 6 mice. We found that there was no significant difference between
the groups in a proportion of CD8+ T lymphocytescompared with CD3+ T lymphocytes(Fig
6A). Fig 6B are representative images of flow cytometry on day 5 after aFP in the control
group and aFP group respectively. The number in the figures represents proportion of CD8+ T
lymphocytes compared with CD3+ Tlymphocytes. However aFP led to a significant decrease
in Treg which suppresses the function of the immunocell on day 5 after aFP, proportions of
Treg compared with CD3 and CD4+ T lymphocyteswere significantly lower in the aFP group
than in control (p< 0.05: Fig 6C and 6D). Fig 6E are representative images of flow cytometry
on day 5 after aFP in the control group and aFP group respectively. The number in the figures
represents proportion of CD4+ Foxp3+ Treg compared with CD4 positive T lymphocytes. This
observation indicates that immunosuppression by Treg in the aFP group is less than in the
control group. Additionally we investigated whether beta-gal epitope (TPHPARIGL) specific
CD8+ T lymphocytes were elicited or not. To detect them, beta-gal specific pentamer was incu-
bated with TILs, anti-CD8, CD4 and Foxp3 antibodies. We found that aFP led to a significant
increase in beta-gal specific CD8+ T lymphocytes compared with total CD8+ T lymphocytes
on day 5 after aFP (p< 0.05: Fig 6F), and moreover in beta-gal epitope specific CD8+ T lym-
phocytes compared with Treg (p< 0.05: Fig 6G).
Repeated experiments are shown in S7 Fig.
Fig 5. Immunohistochemical staining for apoptotic tumor cells. (A and B) Immunohistochemical staining for
apoptotic cells in the tumor 1 day after aFP in the control group and aFP group respectively. Representative images
are shown. Cells stained as red color, which are indicated by white arrow heads are apoptotic cells.
https://doi.org/10.1371/journal.pone.0184852.g005
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aFP induces and Treg suppresses the cytotoxic function of CD8+ T
lymphocytes
To investigate the involvement of adaptive immunity in aFT effect against cancer, we mea-
sured CD8+ T lymphocytes-cytotoxicity against CT26.CL25 colon carcinoma cells using CD8+
T lymphocytes sorted from TILs 5 days after aFP treatment. Control mice had no treatment.
As shown Fig 7A, cytotoxicity assay shows sorted CD8+ T lymphocytes from aFP-treated mice
displayed significantly specific lysis comparing with control mice (p< 0.05; Fig 7A).
Moreover to investigate whether aFP-induced CD8+ T lymphocytes-cytotoxicity was sup-
pressed by Treg, we measured the cytotoxicity with/without CD25+ (which is one of the marker
of the Treg) positive CD4+ T lymphocytes after aFP treatment. Before the investigation, we mea-
sured the percentage of Foxp3+ T lymphocytes of total CD4+ CD25+ T lymphocytes was included
in TIL and the drainage lymph node on day 13 (5 days after aFP treatment). We found that 52%
in control group and 3% in aFP group of the total CD4+ CD25+ T lymphocytes in TIL were
Foxp3 positive (S1B Fig). However 97% in control group and 95% in aFP group of the total CD4+
CD25+ T lymphocytes in the drainage lymph node were Foxp3 positive (S1C Fig). Therefore,
Fig 6. Flow cytometric analysis for tumor infiltrating lymphocytes. (A) proportion of CD8+ T lymphocytes
compared with CD3+ T lymphocytes in the tumor. (B) representative images of flow cytometry for CD8+ T
lymphocytes on day 5 after aFP in the control group and aFP group respectively. The number in the figures
represents proportion of CD8+ T lymphocytes compared with CD3+ T lymphocytes. (C and D) proportion of Treg
compared with CD3 and CD4+ T lymphocytes in the tumor respectively. (E) representative images of flow
cytometry for Treg on day 5 after aFP in the control group and aFP group respectively. The number in the figures
represents proportion of CD4+ Foxp3+ Treg compared with CD4+ T lymphocytes. (F) proportion of beta-gal epitope
specific CD8+ T lymphocytes compared with total CD8+ T lymphocytes in the tumor. (G) proportion of CD8+ T
lymphocytes compared with Treg in the tumor.
https://doi.org/10.1371/journal.pone.0184852.g006
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we focused our study on CD4+ CD25+ T lymphocytes in the drainage lymph node as Treg as sup-
pressor cells due to the high percentage of Foxp3+ cells of CD4+ CD25+ lymphocytes.
We found sorted CD8+ T lymphocytes co-cultured with CD4+ CD25+ T lymphocytes dis-
played significantly decrease of specific lysis against CT26.CL25 cells compared with co-cul-
tured without CD4+ CD25+ T lymphocytes (p< 0.05; Fig 7B). These results indicate that Treg
suppress the cytotoxic function of CD8+ T lymphocyte against cancer cells.
Repeated experiments are shown in S8 Fig.
Adaptive immune system is necessary to eradicate cancer cell after aFP
To corroborate our results indicating that the adaptive immune system is necessary to eradi-
cate cancer cells after aFP, we repeated the experiment with anti-CD8 depletion antibody to
ablate CD8+ T lymphocytes in the mouse. Control group had no treatment. As shown in Fig 8,
treatment of aFP in absence of CD8+ T lymphocytes failed to prevent tumor growth and even-
tual euthanasia, while 2 out of 4 mice in aFP group, no CD8+ T lymphocytes depletion, sur-
vived. (P<0.01; Fig 8B). However even CD8+ T lymphocytes was depleted, aFP led to a
reduction in tumor volume on day 10 and 12 (P<0.001; Fig 8A). This observation indicates
aFP induced apoptosis of cancer cell and then led to a temporal tumor reduction. However
that was insufficient to completely remove the tumor because of lack of activated adaptive
immunity.
Repeated experiments are shown in S9 Fig.
Discussion
This is the first study known to the authors that demonstrates marked tumor size reduction
and initiation of a systemic, tumor specific immune response using FP laser irradiation in the
absence of any additional drugs or adjuvant therapy. FP has been used for a range of clinical
indications, however the ability of FP to induce tumor regression is somehow surprising as FP
treatments are typically used to stimulate wound healing and tissue tissue regeneration. Fur-
ther more the use of FP has generally been limited to achieving localized tissue effects within
the treatment area. FP is typically used for treatment of non-malignant skin conditions, with
few exceptions such as for the treatment of actinic keratoses [11]. To date, the mechanism of
Fig 7. Cytotoxicity assay and Treg function examination. (A) the number in the figures represents %
specific lysis of sorted CD8+ T lymphocytes from TILs against CT26.CL25 cells. Average specific lysis against
CT26.CL25 cells in the aFP group was significantly higher than in the control group (P < 0.05). (B) percentage
of specific lysis CT26.CL25 by sorted CD8+ T lymphocytes from TILs with and without CD4+CD25+ T
lymphocytes (sorted from tumor drainage lymph node).
https://doi.org/10.1371/journal.pone.0184852.g007
Fractional laser exposure induces innate and systemic anti-tumor immunity
PLOS ONE | https://doi.org/10.1371/journal.pone.0184852 September 18, 2017 9 / 22
overall reduction of actinic keratoses within the treatment field is not known and warrants fur-
ther investigation.
aFP has been used successfully for treatment of skin cancer in conjunction with PDT treat-
ment [9, 10]. In such treatments, aFP is used merely as a modality to provide a more effective
response to the PDT treatment by aFP-assisted drug delivery of the photosensitizer, and not
for directly affecting the tumor tissue itself. In some studies, aFP has been used for laser-assis-
ted delivery of a vaccine [24, 25]. The principal role of aFP in vaccine delivery is to improve
permeability of the skin barrier and/or to provide a needle-less alternative to classical injection
techniques. Nevertheless, some studies have also found that aFP in combination with vaccines
may provide a more potent vaccine immune response as compared to mechanical transdermal
vaccine delivery [24, 25].
The concept of using aFP for direct irradiation and intentionally only partial ablation of
a potentially lethal, metastasizing tumor is novel and in marked contrast to conventional
energy-based oncological treatments. The current paradigm of energy-assisted cancer treat-
ment is to cause complete destruction and eradication of the tumor tissue as a direct result of
the laser irradiation. The concept of intentionally damaging only a small fraction of the tumor
is distinct from (and contrary to) current energy-based approaches for tumor treatment.
Hyperthermia of tumor tissue, including laser-assisted hyperthermia or thermal ablation,
has been used previously to induce a systemic tumor response [26]. However, such approaches
appear to be directed only to treatment of either the entire tumor tissue or at least a substantial
portion thereof. Also, non-fractional laser treatments such as, e.g., pulsed dye laser or Nd:YAG
laser treatments have been used to treat local skin cancers [27–29]; however, the objective of
Fig 8. aFP treatment in absence of CD8+ T lymphocytes. (A) tumor volume curves of mice in the control
group (no treatment), anti-CD8+aFP and aFP group after tumor inoculation. ** P < 0.001 comparing control
to anti-CD8+aFP or aFP group. * P < 0.05 comparing anti-CD8+aFP to aFP group. The bars represent SD.
(B) Kaplan-Meier survival curves of mice receiving tumor inoculation. The significance values for the
difference between the survival curves are: control or anti-CD8+aFP vs. FP group (p < 0.01).
https://doi.org/10.1371/journal.pone.0184852.g008
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these treatments was to completely eradicate a tumor either by direct thermal destruction or
by closure of the vessels supplying blood to the tumor, therefore “starving” the tumor cells to
death. It is a novel concept and contradicts previous approaches of tumor treatment to inten-
tionally limit the laser induced tissue damage to only to a very small fraction of the tumor
volume.
We have demonstrated (without introduction of other bioactive substances) that aFP laser
treatment of a particular tumor type can achieve a reduction of tumor size and reject tumor
rechallenge. This is indicative of an immune response that bears some similarities to the
immune response achieved with PDT treatment [17]. This is a remarkable result, as PDT is
dosed and designed to destroy the complete tumor volume, whereas aFP directly destroys only
a small percentage of the tumor tissue. The observed tumor reduction and immune response
in the present study occurred in the absence of any systemically-delivered photosensitizer or
drug.
In this initial study, no assessment of the effects of variation of dosimetry for the tumor
treatment was made. The present aFP studies were each performed using a constant energy of
100 mJ per MTZ (e.g., a single 100 mJ pulse was used to form each ablated hole in the aFP irra-
diation pattern). This energy was chosen as being sufficient to ablate tissue to a substantial
depth within the tumor. For example, the MTZs formed by the 100 mJ pulses extended to
approximately 2/3 of the tumor depth. This energy per MTZ is high compared to settings rou-
tinely used for the most common fractional ablative CO2 laser indications, such as skin rejuve-
nation and wrinkle reduction, which typically vary from about 15 mJ to 100 mJ depending on
the associated pattern density and clinical indication [30]. The dermal thickness of mouse skin
is about 0.29 to 0.41 mm [31], which is significantly thinner than the approximately 0.6 to 2.4
mm dermal thickness of human skin [32].
For this study we have selected a density of 5% which could still be applied safely in the
absence of risk for bulk heating for such relatively high MTZ energies. We could demonstrate
that a thermal injury within a very small percentage of the tumor tissue induced tumor regres-
sion and an immune response stimulation.
It should be noted that the morphology and geometry of ablative fractional lesions within
colon cancer tumor tissue differ substantially as compared to ablative fractional lesions within
skin. In cutaneous tissue, aFP CO2 lesions typically present as regular, straight columns of a
laser-induced hole surrounded by a cuff of thermal injury. These laser-generated passages
appear to be straight and stable, as they are embedded within a collagen rich-tissue and sur-
rounded by a cuff of coagulated collagen, both of which can provide some stability [3]. In
contrast to aFP skin MTZs, the lumen of the laser-created holes in tumor tissue appear to be
collapsed; the amount of thermal injury surrounding ablated MTZs in such tumors is minimal,
and appears to be less than 40 μm thick as assessed by NBTC staining.
This geometry of aFP lesions in colon cancer can be explained by considering anatomical
differences of tumor tissue and skin tissue. First, as the colon cancer tissue grows rapidly, caus-
ing volume expansion, there is an increased intratumoral tissue pressure. Although we have
not measured the pressure within a tumor, this pressure phenomenon during tumor growth
has been observed and described previously [33]. Also, the reduced amounts of collagen within
the tumor is expected to result in decreased mechanical stability as compared to skin tissue. It
seems plausible that the combination of increased intratumoral pressure and reduced tissue
stability can lead to the substantially complete collapse of the laser-ablated holes. Further
investigations of the geometry and collapse of MTZs in tumor tissue during aFP procedures
may reveal important correlations with tumor-specific biology.
The histology that was performed immediately following aFP revealed an increased amount
of erythrocytes in vessels within the tumor volume, suggesting an enhancement of blood flow
Fractional laser exposure induces innate and systemic anti-tumor immunity
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within the tumor resulting from the aFP. This is another observation that bears further detailed
investigation in aFP of tumors. The apparent increase in blood flow in the tumor may facilitate
some limited transport of tumor cells out of the tumor, but also may facilitate access of immune
competent cells to the core region of the tumor. For example, the enhanced tissue pressure within
the core of rapidly-growing tumors can make the core region inaccessible to immune competent
cells, which rely on vascular perfusion of the tumor. We speculate that a temporary increase in
blood flow may result from the partial but sudden vaporization of tumor tissue and the resulting
internal pressure relief during aFP of a tumor. This may facilitate access of immune competent
cells to cancer cells within the tumor.
NBTC staining performed immediately after aFP laser exposure revealed that there was an
absence of bulk heating in the fractionally-treated tissue volume, indicating a lack of confluent
thermal injury within the tumor tissue. This particular thermal injury pattern within the
tumor tissue distinguishes aFP of tumor tissue from prior energy-based tumor treatment
approaches using physical modalities, such as ionizing radiation therapy or classical thermal
ablation approaches, that typically provide a relatively homogenous dose of energy throughout
the tumor tissue.
While extensive and homogenous irradiation of tumors may be desirable for tumor de-
struction, such “full-irradiation” approaches have potential downsides. For example, the sub-
stantially complete destruction of the tumor tissue also destroys nearby immune competent
cells that might be helpful to trigger an immune response. This is of particular concern, e.g., in
radiation therapy because immune competent cells have a low damage threshold and might be
even more vulnerable to a full-irradiation treatment than the tumor cells themselves [34]. Cur-
rent treatments are designed to destroy the tumor, but not to necessarily trigger an immune
response. The death pathway varies with different thermal doses, and it is not clear which path-
way might be the most effective for stimulating an immune response [35].
A fundamental advantage of the thermal damage pattern unique to FP is that throughout
the tumor, cancer cells are exposed to wide range of temperatures that can vary from the nor-
mal body temperature of the host up to the vaporization temperatures generated in the MTZs,
which may be in excess of 100˚C. This wide temperature variation results from the very steep
temperature gradient caused by the focused laser radiation within the location of each MTZ
vs. the immediately adjacent unexposed tissue. Although only one specific aFP treatment pat-
tern and pulse energy was utilized in the present study, triggering of a marked systemic
immune response was observed despite the minimal amount of overall thermal damage done
to the tumor volume. We estimate that only approximately 5% of the total tumor volume was
thermally damaged.
Neutrophilic infiltrates in tumor tissue have been well described previously and may have
positive or negative impact on the immune response. Tumor-associated neutrophils (TANs)
are classified in tumor-bearing mice as N1 or N2 [36]. N1 acts as antitumorigenic immunity
but N2 acts as protumorigenic immunity such as supporter for tumor growth and suppressor
against anti-tumor immune response, depending on the tumor microenvironment [37]. Jab-
lonska et al reported interferon-beta was polarized TAN toward N1 phenotype [38]. Colombo
et al reported G-CSF at the tumor site led the neutrophils activated and aquired cytotoxicity
[39]. Fridlender et al reported N2 phenotype is deriven by the TGF-beta [36]. N2 phenotype is
related with an unfavorable prognosis [40–43]. These reports suggest controlling tumor micro-
environment and a neutrophilic shift to N1 phenotype is desirable for to trigger a favorable
immuneresponse. There are reports that tumors secrete TGF-beta to evade anti-tumor immu-
nity [44, 45]. The secretion induces a N2 phenotype. Mishalian et al reported in established
tumor TAN acuired a more-tumorigenic phenotype [46]. This might be related with increas-
ing secretion of TGF-beta in growing tumor. In our study, aFP induced a Treg level decrease.
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We hypothesize the following meachanism: (1) necrotic and apoptotic tumor cell caused by
thermal injury of aFP lead to tumor reduction and release of damage-associated molecular pat-
terns (DAMPs) [47]. DAMPs recruits neutrophils into the tumor [48] and lead the recruited
neutrophil to shift to N1 phenotype [23]. (2) Decreasing TGF-beta secretion prevents the neu-
trophils to shift to N2 phenotype and Treg to be recruited into the tumor, as TGF-beta is
known to recruit Treg [49]. Chaput el al have demonstrated increased CD8+ T lymphocyte
activity as a result of Treg depletion [50]. Our study also showed Treg suppressed CD8+ T lym-
phocyte activity. This relation between CD8+ T lymphocyte activity and Treg makes it plausi-
ble that depletion of Treg by aFP led to activate CD8+ T lymphocyte in our study. We were
able to demonstrate prevent tumor growth after inoculation. Interestingly, inoculated tumor
on anti-CD8 antibody-treated mice experience a temporary reduction in tumor size and sig-
nificant growth delay shortly after a single aFP treatment. We hypothesize neutrophils played
a role to reduce the tumor because the reduction cannot be explained by tumor ablation due to
direct thermal injury as the volume of the directly thermally damaged tissue was minimal as
compared to the reduction in tumor size and B lymphocytes, NK cells and macrophage cells
were not increased comparing with control group. In spite of the marked temporary reduction
of tumor volume and tumor re-growth no regression was observed in the anti-CD8 antibody-
receiving mice. This observation strongly indicates that adaptive immunity is necessary to
eradicate cancer cells.
The cancer cell we used in this study is the colon CT26.CL25 cancer cells transduced with
lacZ gene to stably express a tumor antigen (beta-gal) which are syngeneic to balb/c, to investi-
gate the effectiveness of aFP treatment against tumor antigens. The cancer cells allowed us to
design study models similar in the clinical situation in order to investigate the importance of
the expression of the tumor antigen after aFP laser treatment. The cytotoxic lymphocyte cell
can recognize and bind the immunodominant peptide epitope derived from beta-gal antigen
on MHC class I haplo type H2Ld on CT26.CL25. However, the beta-gal expression on the cell
in a normal state is not sufficient to stimulate an immune response to prevent tumor growth
[17]. There are many reported studies that utilize this tumor-associated antigen (TAA) prop-
erty to show anti-tumor activity of cancer therapies. Therefore we used aFP as a new approach
for releasing TAA and enhancing anti-tumor immunity in this study. Mroz et al showed
that PDT induced local remission of CT26.CL25 tumor as well as a systemic tumor-specific
immune response, resulting in regression of a remote, untreated antigen-positive tumor, and
suggesting release of TAA (beta-gal) from the tumor by PDT induces systemic tumor-specific
immune response [17]. In our study, pentamer staining revealed beta-gal epitope specific
CD8+ T lymphocytes in treated mice, and the cytotoxic assay and rechallenge examination
also showed systemic tumor-specific immune response of CD8+ T lymphocytes. These results
indicate aFP has the potential to induce a systemic tumor-specific immune response. Interest-
ingly the inoculation as rechallenge of CT26WT tumor which was parental tumor of CT26.
CL25 was rejected in mice cured from CT26.CL25 tumor. We expect release of common TAA
by aFP treatment affects to the rejection. Further investigation of release of the TAA is neces-
sary. There is concern the tumor destruction promotes development of metastasis. However
we expect the metastatic cells are killed by the epitope specific CD8 lymphocytes from this
study. We observed also one mouse in the control group which had tumor regression. It is
feasible that this mouse spontaneously acquired immunity towards the tumor. However most
of the mice in the control group did not acquire sufficient enough immune response to survive
in contrast to the FP treated group. Mroz et al reported P1A antigen-positive tumor-bearing
untreated DBA/2 mice showed slower growth of the tumor and showed better survival than
nude mice [51]. This indicates untreated mice also had an induced immune response against
TAA by the tumor. There is a report regarding enhancement of the incident of metastasis in
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surgically tumor-resected mice caused by operative stress [52]. However in our study there
was no incidence of metastasis after aFP treatment. This suggests that aFP treatment has only
minimal risk for metastasis.
In conclusion, we used aFP to induce tumor regression and systemic tumor immune
response in a balb/c mice model bearing CT26.CL25 tumors. Despite the small degree of ther-
mal injury to the overall tumor, and absence of any introduced drug or other bioactive sub-
stance, aFP was observed to induce innate, adaptive immunity and prevent tumor recurrence
of CT26.CL25 tumors. Moreover, aFP tumor treatment induced long-term immune memory
and resistance to rechallenge. These effects might be mediated by tumor antigen-specific cyto-
toxic T lymphocyte which can recognize the immunodominant epitope of beta-gal induced by
aFP irradiation. Accordingly, a marked tumor-specific systemic immune response was pro-
duced using limited thermal injury and without administration of any bioactive substances.
The effects of aFP at various dosimetry of laser setting, different tumor models, and the effects
of combination therapies of aFP with drugs that induce or enhance tumor immunity and their
mechanism, will also be investigated in further studies. Although we have chosen a fractional
laser modality, other physical modalities capable of inducing a fractional thermal damage pat-
tern, such as focused ultrasound pattern or radiofrequency needle arrays, may also provide
some anti-tumor effects and should be investigated.
Conclusion
The present study indicates that it may be advantageous to apply aFP to tumor tissue to induce
an adaptive immune response. It is notable, that such spatially-disperse pattern of thermal
damage is distinct from conventional approaches of inducing complete and immediate tumor
ablation resulting from a substantially homogenous energy exposure of the entire tumor. We
would like to emphasize that aFP treatment of any cancer or malignant lesion (with the excep-
tion of actinic keratoses) is at this point considered as investigational, and should not be used
as standard of medical care. The results of this animal study encourage further studies to care-
fully investigate the highly promising role of aFP treatments in oncology.
Materials and methods
Cell lines
CT26.CL25 murine colon cancer cell lines (ATCC, Mannassas, VA) was cultured in Dulbecco’s
Modified Eagle’s Medium supplemented with 10% heat-inactivated fetal bovine serum, penicillin
(100 U/mL) and streptomycin (100 mg/mL) (all from Sigma-Aldrich, Natick, MA) at 37˚C in
5% CO2. Culturing was performed in 75 cm
2 flasks (Falcon, Invitrogen, Carlsbad, CA). CT26.
CL25 cells were cultured in a constant presence of 500 μg/mL G418 antibiotic (Sigma-Aldrich,
Natick, MA) in order to maintain a constant expression of the vector
Animals
Six-week-old female BALB/c mice (Charles River Laboratories, Boston, MA) were used for the
study. The care and handling of the animals were done in accordance with a protocol approved
by the Subcommittee on Research Animal Care (IACUC) at Massachusetts General Hospital
(MGH).
Animal tumor model
Mice were inoculated unilaterally at the left leg with 3.5 x 10^5 CT26.CL25 intradermally into
the depilated thigh after being anesthetized through intraperitoneal injection of a cocktail of
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ketamine (90 mg/kg) and xylazine (10mg/kg). Anti-CD8 depletion antibodies (2.43; BioXCell,
West Lebanon, NH) were administered intraperitoneally at a dose of 200 ug per mouse every 3
days from one day before tumor inoculation to removal of mice as endpoint. The tumor vol-
ume was determined by measuring the longest dimension and orthogonal dimension of the
tumor with vernier calipers. Tumor volumes were calculated according to the formula vol-
ume = 4π/3×[(a+b)/4]3, where a and b represent the long and short axis lengths, respectively.
If mice appear to be pain as judged by behavioral traits (flinching, guarding, ruffled fur, pro-
nounced inactivity) during the course of the experiment, they received buprenorphine (0.05
mg/kg) injected subcutaniously or IP every 12 hours for 1 day. If this fails to relieve their pain
they were withdrawn from the study and euthanized by transcardial perfusion using 4% para-
formaldehyde or zinc fixative (BD, Bioscience, Franklin Lakes, NJ) after mice are anesthetized
by intraperitoneal injection of a cocktail of ketamine (180 mg/kg) and xylazine (20mg/kg).
Other indications for removal of mice from the study include tumor size exceeding 1.5 cm in
length, signs of systemic illness and life threatening burn injury manifested by pronounced
inactivity, torpor, ruffled fur, failure to eat and drink and weight loss of 15% or more. If the
tumor cell line injection results in ulcer or laser treatment causes unexpected burn or ulcer the
mouse was euthanized.
Fractional CO2 laser irradiation
Ablative fractional laser exposure was performed on the tumor site at day 8 after tumor cell
inoculation. At that time, the tumors have reached a typical diameter of about 5 mm. Expo-
sures were performed with an Ultrapulse Encore CO2 laser (Lumenis Inc, Yokneam, Israel). A
single aFP treatment was performed within a treatment area of 6×6 mm, with a pulse energy of
100 mJ energy per pulse, at a nominal density of 5% (i.e., 5% within the treatment area surface
was irradiated), one pass, and a repetition frequency of 300 Hz between adjacent MTZs. No
skin cooling was applied and the anesthesia was performed by intraperitoneal injection of a
cocktail of ketamine (90 mg/kg) and xylazine (10mg/kg).
Histological tissue processing
The extent of thermal injury was determined immediately after laser exposure of the tumor
with nitro-blue tetrazolium chloride (NBTC) staining of frozen sections [53]. Tissue sam-
ples were embedded in OCT compound (Sakura Finetek USA, Inc., Torrance, CA), frozen,
and sliced vertically and horizontally into serial 20-μm-thick sections in a cryostat (QS11,
Avantik Biogroup, Springfield, NJ). Frozen sections were incubated with NBTC solution
for 4 hours and counter-stained with eosin. The solution was made with 80 mg of nitro blue
tetrazolium dissolved in 200ml of PBS and 100 mg of β-nicotinamide adenine dinucleotide
(all from Sigma-Aldrich, Natick, MA). The lesion geometry and histology were assessed by
hematoxylin and eosin (H&E)-stained paraffin sections. Tissue fixation was obtained by
performing transcardial perfusion using 4% paraformaldehyde or zinc fixative (10 ml/ each
mouse) immediately after aFP, the aFP-treated tissue samples were excised, and the aFP-
treated tissue samples were placed into formalin. After 72 hours fixation in formalin, each
tissue sample was processed for paraffin embedding, sliced vertically and horizontally into
serial 5-μm-thick sections, and stained with H&E. The lesion geometry and aFP laser pene-
tration depth were assessed using a standard light microscope with a calibrated scale bar.
Representative histologies were photodocumented. The samples which were used to deter-
mine the dimensions of the aFP-treated tissue samples were procured immediately after
aFP.
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Rechallenge
Mice surviving 90 days after tumor inoculation were rechallenged with matched tumor cells
(3.5 x 10^5 CT26.CL25) intradermally in the contralateral (right) thigh against previous inocu-
lation. Age-matched naive mice were inoculated with the same number of the cells in the right
thigh as the controls were. The inoculated mice were monitored for another 60 days to confirm
tumorigenesis. Additionally Mice surviving 60 days after rechallenge experiment with CT26.
CL25 cells were rechallenged with CT26 wild type (CT26WT) colon carcinoma cells (3.5 x
10^5), which is parental cells of CT26.CL25 cells intradermally in the left thigh.
Immunohistochemistry
To confirm whether innate immunity was induced after the fractional laser treatment, immu-
nohistochemistry was performed. Tumors were excised on day 9 (1 days after aFP) and paraf-
fin sections were made using zinc fixative (BD, Bioscience, Franklin Lakes, NJ) in the same
manner as mentioned above. Slides were deparaffinized and washed with PBS or 0.1% triton
solution 5 minutes 3 times. Slides were incubated with 10% goat serum in PBS solution for 60
minutes at room temperature (RT) and next a 1:200 dilution of rat monoclonal anti-Ly-6G
antibody (Abcam, Cambridge, MA) or anti-CD206 antibody (Abcam), or a 1:100 dilution of
rabbit monoclonal anti-cleaved caspase 3 antibody (Cell Signaling Technology, Danvers, MA)
in 10% goat serum in PBS was added for overnight incubation at 4˚C. A 1:200 dilution of fluo-
rescence-labeled secondary goat anti-rat IgG antibody (Life technology, Carlsbad, CA) in 10%
goat serum in PBS was added for 60 minutes at RT on next day. DAPI (Life technology) was
used as a nuclear counterstain. To observe fluorescence, a confocal microscope with wave
lengths of 405, 561 and 640 nm was used (Olympus, Tokyo, Japan).
Flow cytometry analysis
To confirm regulatory T cell (Treg), CD8 lymphocyte and neutrophil were affected by aFP, flow
cytometry analysis was performed. For leukocyte isolation from tumor, fresh CT26.CL25. tumors
were dissociated mechanically filtering through 70 μm strainer on 6 well culture plate with DNaseI
(10 μg/ml, Roche; Nutley, NJ) and collagenase (10 mg/ml, Life technologies) and incubated 60 min-
utes at 37˚C. The dissociated cells were positively selected for CD45 surface expression using CD45
MicroBeads and magnetic-activated cell sorting (MACS) system (Miltenyi Biotec Inc., Auburn,
CA). Then the cells were stained with antibodies CD3-FITC (145-2C11; eBioscience; Santa Clare,
CA), CD4-APC-eFluor780 (RM4-5; eBioscience), CD8a-PE/CY7 (53–6.7; eBioscience), CD11b-PE
(M1/70; eBioscience), CD19-APC (eBio1D3; eBioscience), CD25-PerCP/Cy5.5 (PC61.5; eBiosci-
ence), NKp46-PE (PE 29A1.4; eBioscience), F4/80-PE (BM8; eBioscience) or Ly-6G-PerCP/Cy5.5
(1A8; Bioledgend), for 30 minutes at 4˚C after they were blocked at 4˚C for 15 minutes using PBS
containing 5% BSA and 0.1% sodium azide. Following staining for surface markers, cells were fixed
and permeabilized by Foxp3 / Transcription Factor Staining Buffer Set (eBioscience) according to
the manufacturer’s instructions at room temperature for 30 minutes. After the permeabilization the
cells were stained with Foxp3-APC antibody (MF-14; Bioledgend) at 4˚C over night. Next day the
stained cells were analyzed on FACSCanto (BD Bioscience, Franklin Lakes, NJ).
Pentamer staining
To confirm epitope specific CD8+ T lymphocytes were elicited by aFP treatment, we stained
isolated leukocytes from tumor with epitope (TPHPARIGL) specific pentamer (ProImmune,
Oxford, UK) costaining with anti CD3-FITC (145-2C11; eBioscience; Santa Clare, CA),
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CD4-APC-eFluor780 (RM4-5; eBioscience) and CD8a-PE/CY7 (53–6.7; eBioscience). The
assay was conducted according to the manufacturer’s instructions.
Cytotoxicity assay and Treg function experiment
To acquire more evidence for the involvement of adaptive immunity, we measured CD8+ T
lymphocytes -cytotoxicity against CT26.CL25 colon carcinoma cells using CD8+ T lympho-
cytes sorted from TILs with/without CD25 (which is one of the marker of the Treg) positive
CD4+ T lymphocytes sorted from the drainage lymph node. Cytotoxicity was assessed by
Galacto-Light Plus System (Thermo Fisher Scientific). 5 days after aFP, leukocytes isolation
from tumor and magnetically positive selection by MACS described above and lymphocytes
isolation from tumor drainage lymph node using 70-mm mesh nylon cell strainer (BD Falcon)
were performed. Then CD8+ T lymphocytes from TILs and CD4+ CD25+ T lymphocytes from
the lymph node were sorted using FACSAria Fusion Cell Sorter (BD Biosciences), with anti-
bodies CD8a-PE/CY7 (53–6.7; eBioscience), CD4- APC-eFluor780 (RM4-5; eBioscience) and
CD25- PerCP/Cy5.5 (PC61.5; eBioscience).7.5x10^2 of sorted CD8+ T lymphocytes from
tumor of aFP-treated mice and 100 target cells (CT26.CL25) were dispensed with or without
5.0x10^2 CD4+ CD25+ T lymphocytes from tumor drainage lymph node of untreated tumor-
bearing mice (control group) in 150μL of RPMI with 10% heat inactivated fetal bovine serum,
penicillin (100 U/mL) and streptomycin (100 mg/mL) (all from Sigma, St Louis, MO) to wells
of round bottom 96-well plate. Simultaneously all wells were stimulated with anti-CD3/anti-
CD28 antibodies (5 μg/mL and 2 μg/mL respectively; eBioscience) in the presence of IL-2
(20ng/mL; Bioledgend). CD4+ CD25+ T lymphocytes were stimulated with TGF-beta (5ng/
mL; eBioscience) additinally. 24h after incubation at 37˚C in 5% CO2, 10μL of supernatant
was used to assess beta-galactosidase enzyme activity using Galacto-Light Plus System accord-
ing to manufacturer’s instructions. The percentage of specific lysis was calculated according
to formula: {test beta-galactosidase enzyme release- spontaneous beta-galactosidase enzyme
released}/{maximum beta-galactosidase enzyme released–spontaneous beta-galactosidase
enzyme released}. The maximal release was obtained by incubation of target cells in lysis solu-
tion contained in the kit.
Statistics
All experiments were repeated at least twice. All statistical analyses were performed with
GraphPad Prism 7.0 (GraphPad Software). All values are expressed as the mean ± SD. Flow
cytometric results and cytotoxicity assay were compared with a two-tailed Mann-Whitney test.
Treg function examination was analyzed with a two-tailed Wilcoxon matched pairs signed
rank test. Tumor volumes were compared with a two-tailed Mann-Whitney test (two groups)
or one-way ANOVA (three groups). Survival analysis was performed using the Kaplan-Meier
method and a log-rank test. Values of P < 0.05 were considered statistically significant.
Supporting information
S1 Fig. Flow cytometric analysis for tumor infiltrating NK cells, B lymphocytes and macro-
phages. (A) proportion of NK cell, B lymphocytes and macrophage compared with CD45 posi-
tive leukocytes in the tumor 2 days after aFP of flow cytometric analysis respectively. There
are no significant differences in the cells between both groups. (B) proportion of Foxp3+ cells
of CD4+ CD25+ in the TILs 5 days after aFP of flow cytometric analysis. (C) proportion of
Foxp3+ cells of CD4+ CD25+ in the tumor drainage lymph node 5 days after aFP of flow cyto-
metric analysis.
(PDF)
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S2 Fig. Tumor volume and survival curves after aFP treatment in repeated experiment. (A
and B) tumor volume curves of mice in the control group and aFP group after tumor inocula-
tion.  P< 0.0005. The bars represent SD. (C and D) tumor volume curve of mice in the con-
trol group, and tumor volume curves of cured mice and non-cured mice which are split from
original curve in aFP group.  P< 0.01,  P< 0.005,  P< 0.0005 comparing control to
aFP-non cured group. The bars represent SD. (E and F) Kaplan-Meier survival curves of mice
receiving tumor inoculation. The significance values for the difference between the survival
curves are: control vs. FP (p< 0.0001).
(PDF)
S3 Fig. Tumor volume and survival curves after rechallenge test in repeated experiment.
(A and B) Kaplan-Meier survival curves of mice receiving the rechallenge test with CT26.CL25
cells. The significance values for the difference between the survival curves are: control mice
vs. survival mice (p<0.005). (C and D) Kaplan-Meier survival curves of mice receiving the
rechallenge test with CT26 wildtype cells which is parental tumor of CT26.CL25 cells. The sig-
nificance values for the difference between the survival curves are: control mice vs. survival
mice (p<0.005).
(PDF)
S4 Fig. Flow cytometric analysis for tumor infiltrating neutrophils in repeated experiment.
(A and B) proportion of neutrophil compared with CD45+CD3- leukocytes in the tumor on
day 1 after aFP treatment.
(PDF)
S5 Fig. Immunochemical staining for tumor infiltrating neutrophils in repeated experi-
ment. (A-J) immunohistochemical staining for neutrophil in the tumor 1 days after aFP in the
control group and aFP group respectively. Cells stained as red color are neutrophils. Cells
stained as yellow color are neutrophils expressing CD206.
(PDF)
S6 Fig. Immunochemical staining for apoptotic tumor cells in repeated experiment. (A
and B) Immunohistochemical staining for apoptotic cells in the tumor 1 day after aFP in the
control group and aFP group respectively. Representative images are shown. Cells stained as
red color, which are indicated by white allow head are apoptotic cells.
(PDF)
S7 Fig. Flow cytometric analysis for tumor infiltrating lymphocytes in repeated experi-
ment. (A and B) proportion of CD8+ T lymphocytes compared with CD3+ T lymphocytes in
the tumor. (C and D) proportion of Treg compared with CD3+ T lymphocytes in the tumor.
(E and F) proportion of Treg compared with CD4+ T lymphocytes in the tumor. (G and H)
proportion of beta-gal epitope specific CD8+ T lymphocytes compared with total CD8+ T lym-
phocytes in the tumor. (I and J) proportion of CD8+ T lymphocytes compared with Treg in
the tumor.
(PDF)
S8 Fig. Cytotoxicity assay and Treg function examination in repeated experiment. (A and
B) the number in the figures represents % specific lysis of sorted CD8+ T lymphocytes from
TILs against CT26.CL25 cells. Average specific lysis against CT26.CL25 cells in the aFP group
was significantly higher than in the control group (P< 0.05). (C and D) percentage of specific
lysis CT26.CL25 by sorted CD8 lymphocytes from TILs with and without CD4+CD25+ T
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lymphocytes (sorted from tumor drainage lymph node in control group).
(PDF)
S9 Fig. aFP treatment in absence of CD8+ T lymphocytes in repeated experiment. (A and
B) tumor volume curves of mice in the control group (no treatment), anti-CD8+aFP and aFP
group after tumor inoculation.  P< 0.05 comparing control to anti-CD8+aFP or aFP group.
 P< 0.05 comparing anti-CD8+aFP to aFP group.  P< 0.05 comparing aFP group to con-
trol or anti-CD8+aFP group. The bars represent SD. (C and D) Kaplan-Meier survival curves
of mice receiving tumor inoculation.
(PDF)
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